Directorio

The study uses a placebo, which is a pill that looks real but has no medicine in it. This helps researchers see how well the study drug works. People who join the study can keep taking some of their regular medicines as long as these medicines follow the study rules.

This study follows about 40 mothers and their children who have a condition called tuberous sclerosis complex. The children are 10 years old or younger. The study looks at information from pregnancies, including whether the mother took certain medicines during pregnancy or not. To take part, participants will give consent online, have a short phone call, and complete surveys. With permission, the study team will collect medical records about the pregnancy and the child’s health from birth to now. There are no in person visits, treatments, or procedures. The study only collects information to help doctors learn more about how this condition and certain medicines may affect pregnancy and children.

This study is being done to find out if atropine eyedrops (0.05% atropine, 99.95% inactive solution) and/or special eyeglass lenses are an effective strategy to slow down the progression of myopia for young children with nearsightedness.

We are doing this study to compare the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib. We want to find out if adding gilteritinib to the usual treatment is beneficial for people with acute myeloid leukemia (AML).

We are doing this study to find out if 2 different experimental drug combinations can improve outcomes for people who are newly diagnosed with AML. We want to compare the outcomes from the standard treatment (cytarabine + daunorubicin) to the following experimental regimens:

• Venetoclax + cytarabine + daunorubicin
• Venetoclax + azacitidine

We are doing this study to compare different experimental drug regimens to the usual treatment (cytarabine and daunorubicin) for acute myeloid leukemia (AML). We want to find out which options have the best outcomes. The different drug combinations we will be testing against the usual treatment are:

• daunorubicin and cytarabine liposome
• cytarabine and daunorubicin with venetoclax
• azacitidine and venetoclax
• daunorubicin and cytarabine liposome with venetoclax

We are doing this study to see if blood and bone marrow samples can be tested in a timely manner that allows for the detection of certain markers that could guide cancer treatment.

We are using you or your child's medical information in this study to better understand the diagnosis, treatment, and complications of Spina Bifida.